---
title: "Casi Pharmaceuticals Announces Plan To Submit Ind Application For Cid-103, An Anti-Cd 38 Antibody In Antibody-Mediated Rejection, And Receipt Of A Non-Binding Proposal To Acquire Entire China Business Of The Company"
description: "CASI Pharmaceuticals plans to submit an IND application for CID-103, an anti-CD 38 antibody, by the end of 2024. They have also received a non-binding proposal to acquire their entire China business f"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/207331821.md"
published_at: "2024-06-26T20:18:08.000Z"
---

# Casi Pharmaceuticals Announces Plan To Submit Ind Application For Cid-103, An Anti-Cd 38 Antibody In Antibody-Mediated Rejection, And Receipt Of A Non-Binding Proposal To Acquire Entire China Business Of The Company

> CASI Pharmaceuticals plans to submit an IND application for CID-103, an anti-CD 38 antibody, by the end of 2024. They have also received a non-binding proposal to acquire their entire China business for a purchase price of $40 million.

CASI Pharmaceuticals Inc (CASI.O) :

-   CASI PHARMACEUTICALS ANNOUNCES PLAN TO SUBMIT IND APPLICATION FOR CID-103, AN ANTI-CD 38 ANTIBODY IN ANTIBODY-MEDIATED REJECTION, AND RECEIPT OF A NON-BINDING PROPOSAL TO ACQUIRE ENTIRE CHINA BUSINESS OF THE COMPANY
    
-   CASI PHARMACEUTICALS INC - TO SUBMIT IND APPLICATION FOR CID-103 BY END OF 2024
    
-   CASI PHARMACEUTICALS INC - BOARD GOT A PRELIMINARY NON-BINDING PROPOSAL LETTER DATED JUNE 21, FROM WEI-WU HE, CHAIRMAN OF BOARD AND CEO OF COMPANY
    
-   CASI PHARMACEUTICALS INC - PROPOSED DEAL FOR PURCHASE PRICE OF $40.0 MILLION, WHICH SHALL INCLUDE ASSUMPTION OF UP TO $20.0 MILLION OF INDEBTEDNESS OF COMPANY

### Related Stocks

- [CASI.US - CASI Pharmaceuticals](https://longbridge.com/en/quote/CASI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CASI Pharmaceuticals Receives Drug Registration Certificate for Thiotepa in China | CASI Pharmaceuticals Inc. has received a Drug Registration Certificate for Thiotepa for Injection in China, valid until  | [Link](https://longbridge.com/en/news/275471513.md) |
| CASI Pharmaceuticals Receives China NMPA Approval for Phase 1/2 Clinical Trial of CID-103 in Renal Allograft AMR | CASI Pharmaceuticals Inc. has received approval from the China National Medical Products Administration (NMPA) for a Pha | [Link](https://longbridge.com/en/news/272709819.md) |
| CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing | CASI Pharmaceuticals has closed the second tranche of its US$20 million convertible note financing, issuing a new US$5 m | [Link](https://longbridge.com/en/news/272431475.md) |
| CASI Pharmaceuticals Reports 80% Efficacy in Phase 1 Study of CID-103 for Immune Thrombocytopenia | CASI Pharmaceuticals Inc. reported that its Phase 1 study of CID-103 for immune thrombocytopenia showed 80% efficacy in  | [Link](https://longbridge.com/en/news/272282742.md) |
| CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing | CASI Pharmaceuticals has closed the first tranche of a US$20 million convertible note financing, issuing a US$5 million  | [Link](https://longbridge.com/en/news/271208648.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.